Double-modulation of @entity1487 by @entity1499 and @entity4181 in advanced XXXX .

@entity4181 @entity1 @entity137 @entity295 @entity1500 @entity14 @entity1431 @entity1499 @entity204 @entity1487
A phase II trial was performed to evaluate the efficacy and @entity137 of a double modulation of @entity1487 ( @entity1487 ) by @entity1499 ( @entity1500 ) and @entity4181 (LV) as first line chemotherapy in advanced @entity14 . Between January 1990, and April 1992, 42 @entity1 with metastatic or advanced recurrent (inoperable) @entity14 were entered into the study. Therapy consisted of a sequential combination of @entity1500 , LV and @entity1487 . @entity1500 was administered at a dose of 150 mg/m2 over 20 minutes I.V. infusion at hour (h) 0, followed 19 h later by LV 50 mg/m2 over 2 h infusion. @entity1487 900 mg/m2 was given by I.V. push injection at h 20. Starting 24 h after @entity1500 administration all @entity1 received LV 15 mg/m2 intramuscularly every 6 h for six doses. Treatment was repeated every 15 days until progressive disease, severe @entity137 , or @entity204 . Four @entity1 were considered not evaluable for response. Objective regression (OR) was observed in 14 of 38 @entity1 (37%, 95% confidence interval 23-53%). Two @entity1 (5%) obtained complete response (CR) and 12 (32%) partial response (PR). Median time to treatment failure was 6 months (range 1-21). Median survival for the whole group of @entity1 was 13 months (range 1-27). @entity137 was within acceptable limits but one therapy-related @entity204 due to severe @entity1431 and @entity295 was observed. Double modulation of @entity1487 with @entity1500 and low dose of LV is an active regimen against advanced @entity14 and represents a promising strategy that should be further explored.
